Long-acting injectable cabotegravir was approved for HIV pre-exposure prophylaxis in late 2021. In this interactive webinar, participants will learn about the effectiveness, advantages, and disadvantages of long-acting injectable cabotegravir as well as the clinical and programmatic steps to incorporate it into practice.
